Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jun;39(6):1336–1340. doi: 10.1128/aac.39.6.1336

Interleukin 10 reduces mortality from severe peritonitis in mice.

T Kato 1, A Murata 1, H Ishida 1, H Toda 1, N Tanaka 1, H Hayashida 1, M Monden 1, N Matsuura 1
PMCID: PMC162737  PMID: 7574526

Abstract

Interleukin 10 (IL-10) is known to suppress the induction of proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-1 and is itself induced by monocytes and macrophages during sepsis. We studied the therapeutic efficacy of IL-10 by testing its effect on the survival rate in the murine cecal ligation-and-puncture (CLP) model. Administration of 1 microgram or more of recombinant murine IL-10 6 h after induction of sepsis decreased lethality in septic mice significantly and also suppressed the elevation of circulating TNF after sepsis. However, treatment with the same dose of IL-10 simultaneously or 6 h before induction of CLP had no effect on survival, and treatment with anti-TNF antibody after induction of CLP had no effect on the survival rate. These data suggest that cytokine modulation with IL-10 is a potential candidate for the treatment of sepsis and sepsis-related multiple organ failure.

Full Text

The Full Text of this article is available as a PDF (266.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams J. S., Roncarolo M. G., Yssel H., Andersson U., Gleich G. J., Silver J. E. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992 Jun;127:5–24. doi: 10.1111/j.1600-065x.1992.tb01406.x. [DOI] [PubMed] [Google Scholar]
  2. Alexander H. R., Doherty G. M., Venzon D. J., Merino M. J., Fraker D. L., Norton J. A. Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery. 1992 Aug;112(2):188–194. [PubMed] [Google Scholar]
  3. Baue A. E. The horror autotoxicus and multiple-organ failure. Arch Surg. 1992 Dec;127(12):1451–1462. doi: 10.1001/archsurg.1992.01420120085016. [DOI] [PubMed] [Google Scholar]
  4. Bean A. G., Freiberg R. A., Andrade S., Menon S., Zlotnik A. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun. 1993 Nov;61(11):4937–4939. doi: 10.1128/iai.61.11.4937-4939.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J Exp Med. 1991 Dec 1;174(6):1549–1555. doi: 10.1084/jem.174.6.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bone R. C., Balk R. A., Cerra F. B., Dellinger R. P., Fein A. M., Knaus W. A., Schein R. M., Sibbald W. J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644–1655. doi: 10.1378/chest.101.6.1644. [DOI] [PubMed] [Google Scholar]
  7. Cassatella M. A., Meda L., Bonora S., Ceska M., Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993 Dec 1;178(6):2207–2211. doi: 10.1084/jem.178.6.2207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eskandari M. K., Bolgos G., Miller C., Nguyen D. T., DeForge L. E., Remick D. G. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol. 1992 May 1;148(9):2724–2730. [PubMed] [Google Scholar]
  9. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991 Dec 1;147(11):3815–3822. [PubMed] [Google Scholar]
  10. Fisher C. J., Jr, Dhainaut J. F., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15;271(23):1836–1843. [PubMed] [Google Scholar]
  11. Fisher C. J., Jr, Opal S. M., Dhainaut J. F., Stephens S., Zimmerman J. L., Nightingale P., Harris S. J., Schein R. M., Panacek E. A., Vincent J. L. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993 Mar;21(3):318–327. doi: 10.1097/00003246-199303000-00006. [DOI] [PubMed] [Google Scholar]
  12. Ge Y., Ezzell R. M., Tompkins R. G., Warren H. S. Cellular distribution of endotoxin after injection of chemically purified lipopolysaccharide differs from that after injection of live bacteria. J Infect Dis. 1994 Jan;169(1):95–104. doi: 10.1093/infdis/169.1.95. [DOI] [PubMed] [Google Scholar]
  13. Gérard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 1993 Feb 1;177(2):547–550. doi: 10.1084/jem.177.2.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med. 1993 Apr 1;177(4):1205–1208. doi: 10.1084/jem.177.4.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Howard M., O'Garra A., Ishida H., de Waal Malefyt R., de Vries J. Biological properties of interleukin 10. J Clin Immunol. 1992 Jul;12(4):239–247. doi: 10.1007/BF00918147. [DOI] [PubMed] [Google Scholar]
  16. Jenkins J. K., Malyak M., Arend W. P. The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res. 1994 Feb;13(1):47–54. [PubMed] [Google Scholar]
  17. Marchant A., Bruyns C., Vandenabeele P., Ducarme M., Gérard C., Delvaux A., De Groote D., Abramowicz D., Velu T., Goldman M. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol. 1994 May;24(5):1167–1171. doi: 10.1002/eji.1830240524. [DOI] [PubMed] [Google Scholar]
  18. Marchant A., Devière J., Byl B., De Groote D., Vincent J. L., Goldman M. Interleukin-10 production during septicaemia. Lancet. 1994 Mar 19;343(8899):707–708. doi: 10.1016/s0140-6736(94)91584-9. [DOI] [PubMed] [Google Scholar]
  19. Oka Y., Murata A., Nishijima J., Ogawa M., Mori T. The mechanism of hepatic cellular injury in sepsis: an in vitro study of the implications of cytokines and neutrophils in its pathogenesis. J Surg Res. 1993 Jul;55(1):1–8. doi: 10.1006/jsre.1993.1100. [DOI] [PubMed] [Google Scholar]
  20. Pradier O., Gérard C., Delvaux A., Lybin M., Abramowicz D., Capel P., Velu T., Goldman M. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol. 1993 Oct;23(10):2700–2703. doi: 10.1002/eji.1830231048. [DOI] [PubMed] [Google Scholar]
  21. Roilides E., Pizzo P. A. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis. 1992 Sep;15(3):508–524. doi: 10.1093/clind/15.3.508. [DOI] [PubMed] [Google Scholar]
  22. Silver G. M., Fink M. P. Possible roles for anti- or pro-inflammatory therapies in the management of sepsis. Surg Clin North Am. 1994 Jun;74(3):711–723. [PubMed] [Google Scholar]
  23. Toda H., Murata A., Matsuura N., Uda K., Oka Y., Tanaka N., Mori T. Therapeutic efficacy of granulocyte colony stimulating factor against rat cecal ligation and puncture model. Stem Cells. 1993 May;11(3):228–234. doi: 10.1002/stem.5530110310. [DOI] [PubMed] [Google Scholar]
  24. Toda H., Murata A., Oka Y., Uda K., Tanaka N., Ohashi I., Mori T., Matsuura N. Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood. 1994 May 15;83(10):2893–2898. [PubMed] [Google Scholar]
  25. Wang P., Wu P., Anthes J. C., Siegel M. I., Egan R. W., Billah M. M. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood. 1994 May 1;83(9):2678–2683. [PubMed] [Google Scholar]
  26. Wichterman K. A., Baue A. E., Chaudry I. H. Sepsis and septic shock--a review of laboratory models and a proposal. J Surg Res. 1980 Aug;29(2):189–201. doi: 10.1016/0022-4804(80)90037-2. [DOI] [PubMed] [Google Scholar]
  27. de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov 1;174(5):1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES